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Abstract 
Medically Unexplained Symptoms are highly prevalent in both primary and secondary care 
and are seen in all medical specialties.  For example, fibromyalgia is seen in rheumatology, 
irritable bowel syndrome in gastro-enterology, non-cardiac chest pain in cardiology.  These 
syndromes have been studied in isolation yet there is considerable overlap in symptoms with 
more than half of patients with one MUS fulfilling diagnostic criteria for one other.  This 
suggests that MUS could be ‘lumped’.  However, research has observed that symptom 
overlap is not present between all MUS.  There are differences in pathophysiology and 
cognitive and behavioural responses between syndromes.  This has generated ongoing debate 
as to whether MUS should be ‘lumped’ or ‘split’.  We argue that a transdiagnostic approach 
that is flexible enough to treat specific responses peculiar to certain conditions could 
accommodate both ‘lumping’ and ‘splitting’.   
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Medically unexplained syndromes (MUS) are defined as persistent bodily symptoms with 
functional disability but no explanatory pathology.  They are highly prevalent in both primary 
and secondary care.  In a meta-analysis of medically unexplained symptoms (not syndromes) 
in primary care, the percentage of patients complaining of at least one medically unexplained 
symptom ranged from 40.2% (95% CI 0.9–79.4%; I2 = 98%) to 49% (95% CI 18–79.8%, I2 
= 98%) (Haller et al., 2015).  MUS are associated with high levels of distress and do not 
respond easily to reassurance and simple explanation (Barsky & Borus, 1999). They are seen 
in all medical specialties.  Fibromyalgia (FM) is frequently seen in rheumatology, irritable 
bowel syndrome (IBS) in gastroenterology, non-cardiac chest pain in cardiology, chronic 
fatigue syndrome (CFS) in infectious diseases, non-cardiac chest pain and functional 
palpitations in cardiology, hyperventilation syndrome in respiratory medicine, tension 
headache in neurology and multiple chemical sensitivity in allergy. These syndromes have 
mostly been studied in isolation.  However, research has observed extensive symptom 
overlap with more than half of patients with one MUS condition fulfilling diagnostic criteria 
for at least one other MUS condition (Nimnuan et al., 2001).  For this reason, Wessely et al. 
(1999) suggested advantages to redefining MUS as one syndrome.  Fink and Schroder (2010) 
advocated a new over-arching term, “bodily distress syndrome”, to encompass all the 
different MUS.  They submit that there is now substantial evidence that MUS conditions are 
not clearly distinct disease entities but rather a common phenomenon with different subtypes.  
They describe similarities in diagnostic criteria, aetiology, pathophysiological, neurobiology, 
psychological mechanisms, patient characteristics and treatment response.  Some years earlier 
Yunus (2007) had suggested the generic term “central sensitivity syndrome” which suggests 
that the common mechanism underlying various MUS is central sensitisation which is the 
hyper-excitement of neurons in the central nervous system.   
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However, this “lumping” hypothesis triggered much debate due to criticisms that overlap is 
not present between all the MUS.  For instance, there is little symptomatic overlap between 
IBS and FM.  Furthermore, the pathophysiology is not consistent across syndromes in that 
there is hyperactivity of corticotropin-releasing hormone neurons in FM but hypoactivity in 
CFS (Neeck & Crofford 2000).  From a cognitive behavioural perspective unhelpful beliefs 
and behaviours may differ markedly from one syndrome to another. 
The study of MUS often attracts debate and sometimes controversy. Even the label MUS 
comes under fire. Persistent Physical Symptoms (PPS) is a new patient-centred term that 
refers to MUS.  For several reasons we prefer to use the term PPS.  Firstly, two surveys of 
different populations preferred the term.  One group consisted of healthy subjects (Marks & 
Hunter 2014) and the other group involved patients with CFS (Picariello et al., 2015).  People 
found the term more acceptable as it avoids mind-body dualism and has cross-cultural 
relevance.  Secondly, it includes symptoms associated with medically diagnosed long term 
conditions such as diabetes, rheumatoid arthritis and multiple sclerosis which may present co-
morbidly with MUS.  Thirdly, it also concurs with changes in the latest edition of the 
Diagnostic and Statistics Manual (DSM-5).  The DSM-5 has consolidated previous terms 
including somatization disorder, conversion disorder, hypochondriasis into a new diagnostic 
term, Somatic Symptom Disorder (SDD).  This refers to persistent (6 months or more) and 
clinically significant somatic complaints accompanied by excessive and disproportionate 
health-related thoughts, feelings and behaviours regarding the symptoms (American 
Psychiatric Association, 2013).  We will use the new term PPS to refer to MUS but continue 
to use the term MUS when referring to the work of other authors who have used this term.  
The development and delivery of effective treatments for PPS is important for patients, health 
professionals, the wider healthcare system and the economy.  There is an increasing demand 
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to ensure that this is achieved efficiently in an ‘over-stretched’ healthcare system.  Prevalence 
of MUS in secondary care is approximately 50% and healthcare costs are twice those of other 
patients (Barsky et al. 2005).  Initiatives to meet this demand are being commissioned and 
developed. The Improving Access to Psychological Therapies (IAPT) programme is 
expanding to treat PPS and long term conditions (LTC’s) to increase access in primary care 
(McCrae et al 2015).   
Cognitive Behavioural Therapy (CBT) for PPS has traditionally focussed on developing 
specific treatment programmes for conditions such as Chronic Fatigue Syndrome (CFS) and 
Irritable Bowel Syndrome (IBS).  This approach is supported by a good evidence base.  CBT 
has demonstrated both short and long term efficacy with small effect sizes for MUS (Van 
Dessel, et al., 2014) yet larger treatment effects are seen in specific syndromes such as CFS 
(White et al., 2011) and IBS (Altayer et al., 2011).  
Given the overlap between syndromes and the fact that the stability of diagnoses within 
individuals is low it is highly probable that a number of core transdiagnostic aetiological 
factors underlie the disorders and that common processes perpetuate the symptoms and 
disability. We and others have identified cognitive and behavioural responses to symptoms 
that are common across MUS conditions. For example such cognitive and behavioural 
responses include avoidance of activity and focussing on symptoms (Deary et al., 2007; 
Spence & Moss-Morris, 2007).  In both IBS and CFS participants hold significantly more 
beliefs about the unacceptability of emotions compared to healthy controls (Bowers & Wroe 
2015; Rimes & Chalder 2010).   
The transdiagnostic approach while addressing common processes is flexible enough to 
address issues specific to the disorder. For example, research has identified different 
aetiological pathways for the development of CFS and IBS.  CFS is more likely to develop 
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following infection with glandular fever and IBS following campylobacter infection.  
Depression has been found to be a greater risk factor for CFS yet stress, anxiety and 
perfectionism are important predictors for IBS (Moss-Morris & Spence, 2006, 2007). While 
IBS and CFS share an overall transdiagnostic response of ‘avoidance behaviour’ they 
sometimes differ in the type of avoidance.  IBS patients may respond to their symptoms with 
‘embarrassment-avoidance’. More specifically they may avoid social situations due to fear of 
embarrassment or fear of having an accident.  However, CFS patients often report that they 
avoid activity or exercise in response to the symptom of fatigue due to fear of exacerbating it.  
Co-morbidity of disorders and common processes are also observed in mental disorders.  
Transdiagnostic approaches and unified treatment protocols for mental disorders such as 
anxiety, depression and eating disorders have been developed to address this (Barlow et al., 
2004; Fairburn et al., 2003, Kring & Sloan, 2010).  They focus on identifying the core and 
common maladaptive temperamental, psychological, cognitive, emotional, interpersonal and 
behavioural processes that underlie a range of diagnostic presentations and target these in 
treatment (Newby et al., 2015).  For example, there is evidence of mechanisms that link the 
process of rumination to both depression and anxiety.  In depression, rumination exacerbates 
low mood, negative thoughts about the past, present and future and interferes with problem 
solving. Of course problem solving is the very thing that may lead to the behavioural 
resolution of problems that causes or perpetuates depression.  The same mechanisms have 
also been found to maintain anxiety but cognition is usually focussed on future threat rather 
than the past (Nolen-Hoeksema & Watkins, 2011). 
There is also a growing evidence base for transdiagnostic approaches for mental disorders.  In 
their systematic review and meta-analysis, (Newby et al., 2015) concluded that 
transdiagnostic approaches are as effective as disorder specific treatments for treating anxiety 
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and may be superior for reducing depression.  Similarly, Norton and Barrera (2012) observed 
treatment equivalence between disorder specific and transdiagnostic treatments for anxiety in 
a non-inferiority RCT.    
We have developed a transdiagnostic cognitive behavioural approach for PPS which can also 
be used for long term conditions.  We anticipate that the adapted transdiagnostic approach 
may address the need for efficiency while maintaining the efficacy of larger effects seen in 
specific condition treatment programmes. Our transdiagnostic approach for PPS is guided by 
the use of a transdiagnostic meta-model (see figure 1).  It integrates predisposing and 
precipitating aetiological factors with perpetuating factors. As with most cognitive 
behavioural models, cognitive and behavioural responses are key.  However, emotional 
responses or reactions and their corresponding physiological interactions are also considered 
in the maintenance of symptoms (Brown, 2004; Deary et al., 2007; Yunus 2007).  Two 
explanatory pathways include and exclude pre-morbid physical pathology or 
psychopathology.  Acute and recuperative stress responses are emphasised as are key 
physiological processes that variably interact with other factors to perpetuate symptoms. In 
terms of how this maps onto the treatment process an assessment of these factors and 
processes with each individual influences the development of a formulation.  This is shared 
with the patient to provide explanation for their symptoms and disability and guides the 
selection of interventions and strategies for treatment.  Table 1 summarises the 
transdiagnostic processes with corresponding interventions and strategies that have informed 
the design of the approach. 
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Figure 1:  A transdiagnostic meta-model of Medically Unexplained Symptoms  
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Table 1.  Adapted Transdiagnostic Interventions  
Process Goal of Intervention  Strategy / Technique 
Behavioural Activity / 
exercise  
avoidance  
To increase activity /  
exercise  
Activity monitoring 
Graded exercise 
Behavioural activation  
All or nothing 
approach to 
activity  
To Balance activity, 
responsibilities and 
relaxation  
Activity monitoring and 
scheduling 
Problem solving  
Poor sleep 
routine 
To have good quality  
sleep routine 
Consistent wake up / sleep 
times 
Bed restriction 
Unhealthy 
behaviours 
To maintain healthy  
life-style 
Discussion re: balanced diet 
(with advice from dietician if 
necessary) Education re: 
healthy bowel habits;  
Discussion re: effects of 
alcohol  
Adoption of sleep routine (up  
time & bed and or sleep 
restriction) 
Education re: stress  
Graded exposure Behavioural 
experiments 
Cognitive Fear Avoidance 
Beliefs 
 
To be aware of influence 
of thoughts  
Re-engage in activity /  
Education re: deconditioning  
Behavioural experiments 
Socratic dialogue about 
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exercise thoughts 
Physical 
Attributions 
Understanding anatomy / 
physiology 
To broaden perspective on  
cause   
Encourage flexible 
attributions 
Explanations 
Treatment as behavioural 
experiment 
Catastrophic 
misappraisal 
/’Rogue’ 
representations 
To broaden perspective on 
outcomes  
Normalisation of symptoms 
Cognitive restructuring  
Discussion / socratic 
questioning 
Unhelpful 
thinking / 
worry 
To facilitate objectivity / 
perspective on thoughts 
Cognitive restructuring 
Mindfulness 
Socratic questioning 
Problem solving 
Perfectionism  Raising self esteem without 
achievement focus  
Behavioural experiments – 
Reducing standards to 80% 
Acceptance of self as’ good 
enough’ 
Compassion focussed 
approach 
Lack of 
acceptance 
Promote acceptance Identification of values and 
development of achievable 
meaningful goals 
Discussion of adapting to a 
‘new healthier normal’ 
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Intolerance of 
uncertainty 
Tolerance of uncertainty Worry management 
techniques 
Symptom focus  To broaden focus of 
attention  
Reduce attention to 
body/symptoms 
Discussion re: effects of 
attention 
Attention training  
Distraction  
Emotional  Emotion 
avoidance  
Acceptance of emotions 
Processing of emotions 
Socratic dialogue about 
negative beliefs about 
emotion   
Mindfulness  
Compassion focussed 
approach 
Emotion 
dysregulation 
Emotion regulation Address trauma  
Discussion re: emotional 
processing  
Shame Shame reduction Cognitive restructuring 
‘Shame attacking’ behavioural 
experiments 
Compassion focussed 
approach 
Social Role of 
significant 
others 
Reduce unhelpful 
reinforcements 
Reduce reassurance seeking 
Facilitate a change in others 
behaviours 
 
Negotiate reduction of internet 
searching and reassurance 
seeking 
Liaison with Healthcare 
Professionals   
Rationalise medication with 
agreement from physicians 
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It is important that the transdiagnostic approach is flexible enough to accommodate specific 
responses associated with different symptom clusters whilst focusing on key factors which 
are thought to perpetuate the problem.  In order to bring some clarity to this complex issue we 
have organised factors and processes within a matrix framework.  The Research Domain 
Criteria (RDoc) initiative provides a template for the development of such a framework 
(Morris & Cuthbert, 2012).  It uses a dimensional transdiagnostic approach to capture 
processes (e.g. cognitive, affective, arousal) that are common across disorders.  Adapting the 
framework we propose a two dimensional hierarchical matrix for PPS.  Columns contain the 
superordinate processes:  symptoms; physiological; emotional; cognitive, behavioural and 
social processes.  Rows consist of both broad transdiagnostic processes as well as processes 
specific to conditions or symptom clusters which are potential targets (see table 2). 
Ideally the matrix evolves as research identifies and develops evidence for additional factors 
and processes to populate the matrix cells.  The strength of evidence for each factor or 
process could be visually represented to map strong, medium and weak evidence, creating a 
third dimension.  In addition, moderating factors that determine the route from 
transdiagnostic to specific could form a network of links between factors and processes.  
These are described as divergent trajectories in Nolen-Hoeksema & Watkins, (2011) heuristic 
for developing transdiagnostic models.  They describe how a transdiagnostic risk factor 
results in different disorders in different people or different disorders within the same person 
over time. Ideally these transdiagnostic mechanisms should be assessed frequently during the 
course of treatment so that the process of change can be assessed. In randomised controlled 
trials measuring both transdiagnostic and specific mediators would allow a more robust 
evaluation of their importance (Windgassen et al 2016).    
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The development of the matrix could provide a useful clinical tool to assist treatment 
formulations and for guiding clinicians in their treatment of PPS.  It may also be used for the 
training and professional development of therapists. 
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Table 2: Proposed PPS Matrix 
Condition Symptoms Behavioural 
Processes 
Cognitive 
Processes 
Physiological 
Processes 
Emotional 
Processes 
Social  
Processes 
Transdiagnostic       
CFS       
IBS       
Fibromyalgia       
Non-cardiac 
chest pain 
      
Etc ....       
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Summary and Conclusions 
The high prevalence and complexity of PPS with increased access to treatment in new and 
developing primary care services demands a treatment approach that is effective and also 
‘efficient’ with relative ease of dissemination across the NHS.  Transdiagnostic approaches 
have the potential to provide effective treatment across a range of conditions that often 
present co-morbidly.  Overlap of symptoms and co-morbidity in PPS as well as commonality 
in cognitive and behavioural responses suggests that a transdiagnostic approach may be 
suitable.  We argue that a transdiagnostic approach needs to be flexible enough to 
accommodate specific responses peculiar to certain conditions.  We are currently carrying out 
a randomised controlled trial (RCT) to test the efficacy of such an approach in PPS.   
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